Related Experiment Videos
Clinical observation and comparison of the effectiveness of several oxime cholinesterase reactivators
Abstract:
After passing toxicity and experimental therapeutic tests, four oxime cholinesterase reactivators [PAM (pyridine aldoxime methiodide), PAC (pralidoxime, pyridine aldoxime methylchloride), TMB4 (trimedoxime), and DMO4 (obidoxime, Toxogonin, LüH6)] were compared in clinical trials. All of them proved capable of restoring erythrocyte cholinesterase activity and relieving symptoms and signs of organophosphate insecticide poisoning. Mildly and moderately poisoned patients can be treated by several injections of any one of these drugs alone, but severe cases need the synergistic action of atropine, as well as treatments for two to three consecutive days. Although response to treatment is stronger with TMB4 and DMO4, they are not recommended for routine treatment because of their dangerous adverse side effects.
Insights
Four oxime cholinesterase reactivators effectively restore enzyme activity and alleviate organophosphate poisoning symptoms. While potent, TMB4 and DMO4 are not recommended for routine use due to adverse effects.
Area of Science:
- Toxicology
- Pharmacology
- Clinical Medicine
Background:
- Organophosphate (OP) insecticide poisoning is a significant global health concern.
- Cholinesterase reactivators are crucial in treating OP poisoning by reactivating inhibited acetylcholinesterase.
- Several oxime reactivators have shown efficacy in preclinical and early clinical studies.
Purpose of the Study:
- To compare the clinical efficacy and safety of four oxime cholinesterase reactivators in treating organophosphate insecticide poisoning.
- To evaluate the effectiveness of these reactivators in restoring erythrocyte cholinesterase activity and alleviating clinical symptoms.
- To determine optimal treatment strategies for different severity levels of OP poisoning.
Main Methods:
- Clinical trials were conducted comparing four oxime reactivators: PAM, PAC, TMB4, and DMO4.
- Patients with varying degrees of OP poisoning were treated with these agents.
- Erythrocyte cholinesterase activity, clinical signs, and symptoms were monitored.
Main Results:
- All four oxime reactivators successfully restored erythrocyte cholinesterase activity and relieved symptoms in OP-poisoned patients.
- Mild to moderate cases responded well to single-agent therapy, while severe cases required combination therapy with atropine and prolonged treatment.
- TMB4 and DMO4 demonstrated stronger therapeutic responses but were associated with significant adverse effects.
Conclusions:
- Oxime cholinesterase reactivators are effective in treating organophosphate insecticide poisoning.
- Treatment protocols should be tailored to poisoning severity, with severe cases necessitating combination therapy.
- Despite potent efficacy, TMB4 and DMO4 are not recommended for routine use due to their adverse side effect profiles.